title: Changes in the concentration and distribution of tissue factor pathway inhibitor in Behçet's disease and systemic lupus erythematosus: effect on the prethrombotic state.
abstract: BACKGROUND
  Tissue factor pathway inhibitor (TFPI) is an anticoagulant which modulates the tissue factor (TF) dependent pathway, acting on the factor VIIa/TF complex, factor Xa, and thrombin. Although most TFPI is found in association with plasma lipoproteins and platelets, the functional pool is bound to vascular endothelium and is released into the circulation on stimulation with heparin or low molecular weight heparin (LMWH).
  
  
  OBJECTIVE
  To assess the vascular endothelial TFPI pool in patients with Behçet's disease (BD) or systemic lupus erythematosus (SLE).
  
  
  METHODS
  Plasma TFPI concentrations were determined before, and 20 and 60 minutes after subcutaneous LMWH injection in 15 newly diagnosed patients with BD and 12 with SLE, and in 12 healthy controls.
  
  
  RESULTS
  Baseline median TFPI was 149.5 ng/ml in healthy subjects, and the percentage change in TFPI at 20 minutes (((value at 20th min - baseline value)/baseline value) x 100) was 575.2. TFPI concentrations in patients with BD were initially normal at baseline (136.0 ng/ml), but the percentage change (44.7) was significantly lower than in the patients with SLE and the controls. Baseline TFPI concentrations in patients with SLE (83.0 ng/ml) were lower than in the control group, but the TFPI response to stimulation with LMWH reached a level (626.4%) comparable to that of the controls.
  
  
  CONCLUSIONS
  Depletion of the functional endothelial pool in BD and low circulating concentrations of TFPI despite an intact pool in SLE may be important in the pathogenesis of thrombosis in these vasculitic syndromes.
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey. ermanm@tr.net
authors.forename: I
authors.initials: I
authors.lastname: Ertenli
authors.forename: S
authors.initials: S
authors.lastname: Kiraz
authors.forename: I C
authors.initials: IC
authors.lastname: Celik
authors.forename: C
authors.initials: C
authors.lastname: Haznedaroglu
authors.forename: M
authors.initials: M
authors.lastname: Erman
authors.forename: M
authors.initials: M
authors.lastname: Calgüneri
authors.forename: S
authors.initials: S
authors.lastname: Kirazli
mesh_terms: D000328:Adult; D001528:Behcet Syndrome / Q000097:blood* / Q000150:complications; D001800:Blood Specimen Collection / Q000379:methods; D065427:Factor Xa Inhibitors; D005260:Female; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008180:Lupus Erythematosus, Systemic / Q000097:blood* / Q000150:complications; D008297:Male; D015842:Serine Proteinase Inhibitors / Q000097:blood; D019851:Thrombophilia / Q000097:blood* / Q000209:etiology
chemical_list: D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D008074:Lipoproteins; D015842:Serine Proteinase Inhibitors; C051928:lipoprotein-associated coagulation inhibitor